Excelsior Medical Co., Ltd. (4104.TW)
TWD 86.6
(-0.46%)
TWD 86.6
(-0.46%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 8.23 Billion TWD | 14.64% |
| 2022 | 7.18 Billion TWD | 9.34% |
| 2021 | 6.57 Billion TWD | -1.53% |
| 2020 | 6.67 Billion TWD | 3.38% |
| 2019 | 6.45 Billion TWD | 1.77% |
| 2018 | 6.34 Billion TWD | 4.1% |
| 2017 | 6.09 Billion TWD | -1.78% |
| 2016 | 6.2 Billion TWD | 0.05% |
| 2015 | 6.2 Billion TWD | 6.82% |
| 2014 | 5.8 Billion TWD | 1.14% |
| 2013 | 5.74 Billion TWD | -4.3% |
| 2012 | 5.99 Billion TWD | 0.08% |
| 2011 | 5.99 Billion TWD | -60.96% |
| 2010 | 15.35 Billion TWD | 7.38% |
| 2009 | 14.3 Billion TWD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 2.16 Billion TWD | 5.81% |
| 2024 Q1 | 2.04 Billion TWD | -6.5% |
| 2023 Q4 | 2.18 Billion TWD | 8.24% |
| 2023 Q2 | 2.02 Billion TWD | 0.8% |
| 2023 Q3 | 2.01 Billion TWD | -0.13% |
| 2023 FY | 8.23 Billion TWD | 14.64% |
| 2023 Q1 | 2 Billion TWD | 2.21% |
| 2022 Q2 | 1.67 Billion TWD | -1.99% |
| 2022 Q3 | 1.84 Billion TWD | 9.96% |
| 2022 Q4 | 1.96 Billion TWD | 6.62% |
| 2022 FY | 7.18 Billion TWD | 9.34% |
| 2022 Q1 | 1.7 Billion TWD | -4.43% |
| 2021 FY | 6.57 Billion TWD | -1.53% |
| 2021 Q3 | 1.57 Billion TWD | -0.29% |
| 2021 Q4 | 1.78 Billion TWD | 13.44% |
| 2021 Q1 | 1.62 Billion TWD | -2.45% |
| 2021 Q2 | 1.58 Billion TWD | -3.0% |
| 2020 Q2 | 1.58 Billion TWD | -8.51% |
| 2020 Q1 | 1.73 Billion TWD | 1.73% |
| 2020 Q3 | 1.68 Billion TWD | 6.29% |
| 2020 Q4 | 1.67 Billion TWD | -0.91% |
| 2020 FY | 6.67 Billion TWD | 3.38% |
| 2019 Q2 | 1.54 Billion TWD | -3.2% |
| 2019 Q4 | 1.7 Billion TWD | 5.91% |
| 2019 FY | 6.45 Billion TWD | 1.77% |
| 2019 Q1 | 1.59 Billion TWD | -2.2% |
| 2019 Q3 | 1.6 Billion TWD | 4.02% |
| 2018 Q4 | 1.63 Billion TWD | 2.55% |
| 2018 FY | 6.34 Billion TWD | 4.1% |
| 2018 Q3 | 1.59 Billion TWD | 1.76% |
| 2018 Q2 | 1.56 Billion TWD | 0.84% |
| 2018 Q1 | 1.55 Billion TWD | -1.37% |
| 2017 Q3 | 1.51 Billion TWD | 0.01% |
| 2017 Q1 | 1.48 Billion TWD | -7.33% |
| 2017 Q2 | 1.51 Billion TWD | 2.0% |
| 2017 FY | 6.09 Billion TWD | -1.78% |
| 2017 Q4 | 1.57 Billion TWD | 3.76% |
| 2016 Q1 | 1.49 Billion TWD | -5.08% |
| 2016 Q2 | 1.56 Billion TWD | 4.92% |
| 2016 Q3 | 1.54 Billion TWD | -1.02% |
| 2016 Q4 | 1.6 Billion TWD | 3.7% |
| 2016 FY | 6.2 Billion TWD | 0.05% |
| 2015 Q2 | 1.57 Billion TWD | 6.68% |
| 2015 Q1 | 1.47 Billion TWD | -1.21% |
| 2015 FY | 6.2 Billion TWD | 6.82% |
| 2015 Q3 | 1.59 Billion TWD | 1.34% |
| 2015 Q4 | 1.56 Billion TWD | -1.34% |
| 2014 Q4 | 1.48 Billion TWD | 1.79% |
| 2014 Q3 | 1.46 Billion TWD | -0.66% |
| 2014 Q1 | 1.38 Billion TWD | -10.81% |
| 2014 FY | 5.8 Billion TWD | 1.14% |
| 2014 Q2 | 1.47 Billion TWD | 6.74% |
| 2013 Q3 | 1.44 Billion TWD | 0.4% |
| 2013 Q1 | 1.3 Billion TWD | -8.31% |
| 2013 FY | 5.74 Billion TWD | -4.3% |
| 2013 Q4 | 1.54 Billion TWD | 7.06% |
| 2013 Q2 | 1.43 Billion TWD | 10.06% |
| 2012 Q4 | 1.42 Billion TWD | -0.58% |
| 2012 Q3 | 1.43 Billion TWD | -13.2% |
| 2012 Q2 | 1.65 Billion TWD | 11.5% |
| 2012 FY | 5.99 Billion TWD | 0.08% |
| 2012 Q1 | 1.48 Billion TWD | 120.01% |
| 2011 Q2 | 4.26 Billion TWD | -1.39% |
| 2011 Q1 | 4.32 Billion TWD | 6.69% |
| 2011 FY | 5.99 Billion TWD | -60.96% |
| 2011 Q4 | -7.41 Billion TWD | -253.73% |
| 2011 Q3 | 4.82 Billion TWD | 13.1% |
| 2010 Q3 | 3.99 Billion TWD | 4.84% |
| 2010 FY | 15.35 Billion TWD | 7.38% |
| 2010 Q4 | 4.05 Billion TWD | 1.46% |
| 2010 Q1 | 3.5 Billion TWD | 0.0% |
| 2010 Q2 | 3.8 Billion TWD | 8.74% |
| 2009 FY | 14.3 Billion TWD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Apex Medical Corp. | 2.64 Billion TWD | -211.253% |
| OK Biotech Co., Ltd. | 1.19 Billion TWD | -591.221% |
| Applied BioCode Corporation | 395.16 Million TWD | -1984.996% |